The Competitive Intelligence Report Immunotherapy of Alzheimer’s Disease as of May 2012 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease including those targeting amyloid-beta (beta-amyloid) and tau. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for passive and active imunotherapy of Alzheimer’s disease. In addition, the report lists company-specific R&D pipelines of immunotherapeutics for Alzheimer’s disease. Competitor projects are listed in a tabular format providing Information on:
Target / Mechanism of Action,
Class of Compound,
Product category/Therapeutic Area,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) Passive Immunotherapy
Antibodies against amyloid
Antibodies against tau
Antibodies against other targets
Intravenous Immunoglobulin (IVIG)
2) Active Immunotherapy
Vaccines against amyloid
Vaccines against tau
3 ) Corporate AD Immunotherapy R&D Pipelines
4) About La Merie